Dublin, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The "Contrast Media - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The global market for Contrast Media is projected to reach US$5.3 billion by 2025, driven by the growing number of imaging procedures such as X-Rays, MRI, CT, and Ultrasound supported by the prevalence of chronic diseases among the growing global population and the ensuing diagnostic burden and demand for imaging services. The global burden of chronic diseases can be put into perspective by the fact that it is the leading cause of death and disability in the world. Although easily preventable, chronic diseases such as heart disease, stroke, cancer, type-2 diabetes, obesity, thyroidism, and arthritis push up healthcare costs and also demand for healthcare services. By 2030, chronic diseases will emerge to be the most costly and prevalent killer worldwide. As a result, healthcare spending is forecast to reach a mind-bending US$19 trillion by the year 2040. A major portion of this expenditure will be spent on medical imaging procedures such as X-Rays, CT scan, MRI, ultrasound, and nuclear medicine imaging, including positron-emission tomography (PET), among other emerging hybrid imaging technologies. As an extremely important aspect of medical practice, imaging has and still continues to revolutionize the world of healthcare. Medical imaging helps in early detection and diagnosis of diseases at a stage when they can be easily treated and of late has been assuming even greater importance as the world healthcare migrates to the tenets of preventative care. Better diagnosis has a direct and a positive impact on therapy procedures and treatment planning. The rise of imaging based surgical strategies to safely handle complicated surgeries is also helping push up the importance of medical imaging.

A key element of the ongoing healthcare reforms and the migration to value based care is medical imaging. Technologies such as nuclear medicine (imaging), molecular imaging, and contrast enhanced radiology procedures are benefiting significantly for the simple reason that there can be no value based care without value based imaging activities. Medical imaging remains very crucial in healthcare as it plays a decisive role in enabling low-cost effective patient care. The starting point for effective treatment is high-performance imaging and accurate diagnosis. Replacing low-value imaging with high performance imaging reduces costs and enhances effectiveness of treatment. In this regard, contrast enhanced imaging and the benefits offered are a perfect value creation. Contrast agents help in advanced visualization of biological structures; and helps capture hard-to-image anatomical regions. They help eliminate errors caused by radiologist's perception which tends to influence interpretation of the true structure of the underlying anatomy. Oral, intravenous, rectal, and intrathecal contrast agents are indispensable today in the practice of radiology for their most primary benefit which is enhanced visibility of internal structures. Efficiency of contrast media over the years have evolved from high-osmolar contrast media (HOCM) which have limited utility and higher side-effects to low-osmolality contrast agents. The development of nonionic compounds marked a major step forward. The most recent type of contrast agent developed is the iso-osmolar contrast media (IOCM) which is composed of dimers, a molecule with two benzene rings and 3 iodine atoms.

The United States and Europe represent large markets worldwide with a combined share of 66.9% of the market. China ranks as the fastest growing market with a CAGR of 5% over the analysis period supported by the remarkable progress made by the country in developing its primary health-care system. Access to and affordability of healthcare services have improved significantly over the last decade. Improving access to timely care is helping drive demand for imaging services in the country.

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

• AMAG Pharmaceuticals, Inc. (USA)

• Bayer Healthcare LLC (USA)

• Bracco Imaging SpA (Italy)

• GE Healthcare (USA)

• Genovis AB (Sweden)

• Guerbet Group (France)

• J.B. Chemicals & Pharmaceuticals Ltd. (India)

• Jodas Expoim (India)

• Lantheus Medical Imaging, Inc. (USA)

• Magnus Health (India)

• Medtronic Plc. (Ireland)

• nanoPET Pharma GmbH (Germany)

• Sanochemia Pharmazeutika AG (Austria)

• Spago Nanomedical AB (Sweden)

• Taejoon Pharm Co., Ltd. (South Korea)

• Unijules Life Sciences Ltd. (India)

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/pce2xd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900